Co-Diagnostics annual operating margin
2017
2018
2019
2020
2021
2022
2023
2024
2025
Co-Diagnostics's operating margin was −8,058.83% for fiscal 2025.
View full Co-Diagnostics company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −8,058.83% | −7035.09 pp |
| 2024 | 2024-12-31 | −1,023.75% | −396.82 pp |
| 2023 | 2023-12-31 | −626.92% | −548.08 pp |
| 2022 | 2022-12-31 | −78.85% | −125.91 pp |
| 2021 | 2021-12-31 | 47.06% | −8.87 pp |
| 2020 | 2020-12-31 | 55.93% | +2797.53 pp |
| 2019 | 2019-12-31 | −2,741.61% | +12587.04 pp |
| 2018 | 2018-12-31 | −15,328.65% | +44238.92 pp |
| 2017 | 2017-12-31 | −59,567.57% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −3,732.47% | +1213.68 pp |
| Q1 2026 | 2026-03-31 | −6,309.12% | +10700.56 pp |
| Q4 2025 | 2025-12-31 | −10,056.68% | −2082.78 pp |
| Q3 2025 | 2025-09-30 | −4,824.49% | −3228.13 pp |
| Q2 2025 | 2025-06-30 | −4,946.14% | −4657.08 pp |
| Q1 2025 | 2025-03-31 | −17,009.68% | −14816.82 pp |
| Q4 2024 | 2024-12-31 | −7,973.90% | −7641.28 pp |
| Q3 2024 | 2024-09-30 | −1,596.36% | −1232.68 pp |
| Q2 2024 | 2024-06-30 | −289.06% | +5774.67 pp |
| Q1 2024 | 2024-03-31 | −2,192.86% | −539.81 pp |
| Q4 2023 | 2023-12-31 | −332.62% | +1531.22 pp |
| Q3 2023 | 2023-09-30 | −363.68% | −235.39 pp |
| Q2 2023 | 2023-06-30 | −6,063.74% | −5981.18 pp |
| Q1 2023 | 2023-03-31 | −1,653.05% | −1696.33 pp |
| Q4 2022 | 2022-12-31 | −1,863.84% | −1914.37 pp |
| Q3 2022 | 2022-09-30 | −128.29% | −173.57 pp |
| Q2 2022 | 2022-06-30 | −82.56% | −125.66 pp |
| Q1 2022 | 2022-03-31 | 43.28% | −8.33 pp |
| Q4 2021 | 2021-12-31 | 50.53% | −8.52 pp |
| Q3 2021 | 2021-09-30 | 45.28% | −9.89 pp |
| Q2 2021 | 2021-06-30 | 43.10% | −18.08 pp |
| Q1 2021 | 2021-03-31 | 51.61% | +121.48 pp |
| Q4 2020 | 2020-12-31 | 59.05% | +1554.36 pp |
| Q3 2020 | 2020-09-30 | 55.17% | +4037.62 pp |
| Q2 2020 | 2020-06-30 | 61.18% | +2279.27 pp |
| Q1 2020 | 2020-03-31 | −69.87% | +36826.95 pp |
| Q4 2019 | 2019-12-31 | −1,495.31% | +15350.76 pp |
| Q3 2019 | 2019-09-30 | −3,982.45% | +13176.89 pp |
| Q2 2019 | 2019-06-30 | −2,218.09% | +11739.90 pp |
| Q1 2019 | 2019-03-31 | −36,896.82% | −23722.00 pp |
| Q4 2018 | 2018-12-31 | −16,846.07% | +52632.76 pp |
| Q3 2018 | 2018-09-30 | −17,159.33% | +11265.32 pp |
| Q2 2018 | 2018-06-30 | −13,957.98% | — |
| Q1 2018 | 2018-03-31 | −13,174.82% | — |
| Q3 2017 | 2017-09-30 | −69,478.83% | — |
| Q2 2017 | 2017-06-30 | −28,424.66% | — |
Over the last five reported fiscal years, Co-Diagnostics's operating margin decreased from 55.93% to −8,058.83%, a change of −8114.76 percentage points. The latest reported quarter, Q2 2026, shows −3,732.47%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Co-Diagnostics filings at SEC.gov ↗